Potenza

• PIrfenidone to prevent fibrOsis in ARDS. A RaNdomizEd controllEd tRial - PIONEER Pending
  2024-514355-16-01 5 Acute Respiratory Distress Syndrome (ARDS)
• The effect of phoSPHocreatine on mEdical emergency team (met) tREated patients: a randomized clinical trial protocol – SPHERE Pending
  2024-518474-14-00 5 respiratory arrest
• OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending
  2025-520554-11-00 5 Cardiovascular Disease
• Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimari … Pending
  2025-521651-22-00 4 hormone receptor positive, HER2-negative breast cancer
• Sodium-glucose cotransporter-2 inhibitors to stabilize coronary ather-osclerosis progression after acute myocardial infarction in women and … Pending
  2025-523375-29-00 5 Myocardial Infarction
• A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High R … Recruiting
  2025-523037-25-00 4 2026-03-10 Patients at high risk for Cardiac Surgery Associated – Acute Kidney In
• ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting
  2025-522960-34-00 5 2026-02-09 Established cardiovascular disease
• Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 Recruiting
  2024-519669-23-00 4 2025-09-29 Patients with metastatic colorectal cancer (mCRC) RAS-mutant
• Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C … Recruiting
  2024-515445-42-00 5 2025-03-24 Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
• The use of Landiolol in mitral valve sUrgery: a raNdomized, controlled, double-blind triAl. (LUNA) Recruiting
  2024-515934-34-00 6 2025-01-28 Low-cardiac output syndrome (LCOS)
• Randomized phase 2 study of Valproic acid combinEd with rechallenge anti-EGFR based regimen regimens in pretreated patients with RAS/BRAF wi … Recruiting
  2024-514420-16-00 4 2024-12-18 RAS/BRAF wild-type metastatic colorectal cancer
• Treatment with a single drug that prevents blood clot formation followed by an anticoagulant drug in patients with irregular heartbeat who h … Recruiting
  2023-509717-36-00 5 2024-12-16 AF patients who have undergone successful PCI
• Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI … Recruiting
  2024-517863-22-00 5 2024-12-01 Study population consists in patients with a diagnosis of mCRC who hav
• Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting
  2023-509551-14-00 5 2024-06-12 Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
• Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting
  2024-511397-70-00 4 2024-05-06 metastatic renal cell carcinoma (mRCC)
• Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patie … Recruiting
  2023-506662-31-00 4 2024-02-28 Gastric or gastroesophageal cancer
• A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting
  2022-502113-28-00 5 2024-02-01 Follicular lymphoma
• Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RA … Recruiting
  2024-518534-81-00 4 2021-07-01 metastatic colorectal cancer
• NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta … Recruiting
  2024-519007-10-00 10 2020-10-22 Locally advanced stage II/III rectal cancer
• VshoRT-R3: Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperatIve treatment in low-moderate risk r … Recruiting
  2024-513920-40-00 9 2013-01-11 low- risk rectal cancel
• A Phase 3 Study of VX-121 Combination Therapy in Subjects With Cystic Fibrosis Ended recruitment
  2024-514173-22-00 5 2023-02-28 Cystic Fibrosis
• Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor Long-term Safety and Efficacy in Subjects Without F508del Ended recruitment
  2024-515637-14-00 5 2022-11-08 Cystic Fibrosis
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• Adjuvant therapy in stage IV colorectal cancer patients NED Ended recruitment
  2024-518217-26-00 4 2021-10-20 Stage IV colorectal cancer patients with no evidence of disease (NED)

Showing 1–24 of 30 trials